AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus ...

SHANGHAI, Nov. 7 (Xinhua) -- In the vast and intricately designed National Exhibition and Convention Center (Shanghai), where ...

SHANGHAI, Nov. 7 (Xinhua) -- In the vast and intricately designed National Exhibition and Convention Center (Shanghai), where ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that could ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate ... sales this year from an ever-lengthening list of indications associated with type 2 ...

A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...

Reliance Power, Nykaa, 3M India, Sula Vineyards, BASF India, Natco Pharma, and Rattanindia Enterprises are among other firms ...

particularly her agency’s move to block Sanofi’s planned purchase of the small drugmaker Maze Therapeutics last year. New ...

PrivateThe Q2 earnings season has crossed the peak and is now nearing the end of the season. Out of 4699 companies listed on exchanges, 1852 companies have already declared their quarterly financials ...

A Winnipeg mother with a newborn is pleading with the province to start offering RSV shots to all babies. As we navigate ...